Dynamic shifts management, Assif replaces Laskey at helm
Dynamic Healthcare Technologies is one of the many health IT companies shuffling top management in an effort to compensate for tougher market conditions. Mitch Laskey, who founded Dynamic and has served as its president and CEO, has stepped
Dynamic Healthcare Technologies is one of the many health IT companies shuffling top management in an effort to compensate for tougher market conditions. Mitch Laskey, who founded Dynamic and has served as its president and CEO, has stepped aside to become a consultant to the company. Christopher Assif, formerly president of Dynamic's Internet Solutions group, has replaced Laskey as CEO. John Fingado, formerly vice president and general manager of CoPath, has been appointed president and COO. Dynamic will concentrate its marketing on the CoMed product suite, which offers clinical connectivity and ASP-based products for laboratory, pathology, and radiology departments.
In related news, Dynamic has expanded the size of its board to seven members from five. Assif and Christopher Cooper, president of Plangent Systems and cofounder of Collaborative Medical Systems (a company acquired by Dynamic in 1996), are the newest appointees. Laskey has retained his seat on the board of directors.
© 2000 Miller Freeman Inc.
11/29/00, Issue # 117, page 3.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
